Physician profile
William Tettelbach
NPI 1336143361
$82,188.57
in general payments reported to CMS, 2019-2025
12 companies · $70K in 2025
The $70K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,250 · 2021: $46.07 · 2023: $1,148 · 2024: $6,551 · 2025: $70K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $71K · Travel and Lodging: $3,652 · Food and Beverage: $3,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $70,750.00 |
| Travel and Lodging | $3,651.53 |
| Food and Beverage | $3,490.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biowound Solutions, INC. | $73,651.53 | 2024-2025 | Bio-Connekt |
| Kci USA, INC. | $4,272.40 | 2019-2023 | Activ.A.C., 3m Coban |
| Organogenesis INC. | $1,227.72 | 2024-2025 | Affinity, Puraply Wound Matrix, Apligraf |
| Mimedx Group, INC. | $931.29 | 2024-2025 | |
| Bone Support INC. | $750.00 | 2023 | Ceramentbone Void Filler |
| Kerecis Limited | $516.24 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Smith+Nephew, INC. | $393.96 | 2024-2025 | Stravix, Renasys Touch, Renasys Go V2 Home |
| Integra Lifesciences Corporation | $144.34 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Surgenex LLC | $143.87 | 2025 | Surgraft, Ardeograft, Pellograft |
| Reprise Biomedical, INC. | $71.66 | 2025 | Miro3d |
| Acera Surgical, INC. | $46.07 | 2021 | |
| Solventum Corporation | $39.49 | 2025 | Promogran Prisma, Activ.A.C., Adaptic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Tettelbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.